PARP2
PARP2 (Poly [ADP-ribose] polymerase 2) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Breast cancer and Prostate cancer.
Overview
Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair. Mediates glutamate, aspartate or serine ADP-ribosylation of proteins: the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units. Serine ADP-ribosylation of proteins constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.89, animal model 0.32, genetic association 0.00, clinical 0.99).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PARP2 (Poly [ADP-ribose] polymerase 2) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Breast cancer and Prostate cancer.
- 1 · What it is
PARP2 (Poly [ADP-ribose] polymerase 2) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Breast cancer and Prostate cancer.
- 2 · What goes wrong in cancer
Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair.
- 3 · How drugs use it
No product in this corpus aims at PARP2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:272 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UGN5 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000129484 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: prostate cancer 0.55, ovarian cancer 0.60, breast cancer 0.57 (GraphQL API, CC0))
Biology
Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair. Mediates glutamate, aspartate or serine ADP-ribosylation of proteins: the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units. Serine ADP-ribosylation of proteins constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage. Mediates glutamate and aspartate ADP-ribosylation of target proteins in absence of HPF1. Following interaction with HPF1, catalyses serine ADP-ribosylation of target proteins; HPF1 conferring serine specificity by completing the PARP2 active site. PARP2 initiates the repair of double-strand DNA breaks: recognises and binds DNA breaks within chromatin and recruits HPF1, licensing serine ADP-ribosylation of target proteins, such as histones, thereby promoting decompaction of chromatin and the recruitment of repair factors leading to the reparation of DNA strand breaks. Location: Nucleus; Chromosome (UniProt). Locus 14q11.2 (HGNC).
- Ovarian cancer: Open Targets association 0.60 with ovarian cancer (MONDO_0008170)
- Breast cancer: Open Targets association 0.57 with breast cancer (MONDO_0007254)
- Prostate cancer: Open Targets association 0.55 with prostate cancer (MONDO_0008315)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99; UniProt keyword "DNA repair". Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PARP2" OR ABSTRACT:"PARP2" OR TITLE:"poly ADP-ribose polymerase 2" OR ABSTRACT:"poly ADP-ribose polymerase 2" OR TITLE:"Poly [ADP-ribose] polymerase 2" OR ABSTRACT:"Poly [ADP-ribose] polymerase 2" OR TITLE:"ARTD2" OR ABSTRACT:"ARTD2" OR TITLE:"ADPRTL2" OR ABSTRACT:"ADPRTL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PARP2, not a curated reading list.